{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:12:51Z","timestamp":1792699971485,"version":"4.5.0"},"reference-count":105,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Globally, high mortality is brought on by RNA viruses, which are linked to chronic human\ndisorders. Viruses dominate the WHO's current ranking of the top 10 global health hazards,\nespecially RNA viruses. RNA viruses, like HIV, SARS-CoV-2, and influenza, which are among\nthe most prevalent and frequently encountered RNA viruses, use RNA as their genetic material,\nmaking them prone to quick changes. They adapt rapidly, complicating the body's immune responses.\nHIV, a significant retrovirus, infiltrates the immune system, causing AIDS by compromising\ndefenses against infections. SARS-CoV-2, which led to COVID-19, sparked a worldwide pandemic\nwith respiratory symptoms, emphasizing the need for research and therapeutic innovations.\nThe COVID-19 pandemic has demonstrated the insufficiency of available resources in effectively\naddressing emerging viral infections. Influenza, a seasonal RNA virus, triggers flu outbreaks, impacting\npublic health. Research is crucial to understanding how these viruses interact with hosts,\naiding the development of effective treatments and strengthening our ability to face new viral\nthreats. The most effective defenses against viral illnesses are virus-specific vaccinations and antiviral\ndrugs. The present review emphasizes the prevalence of the three most pathogenic and widespread\nRNA viruses, namely HIV, influenza, and SARS-CoV2, their pathophysiology, and the current\ntreatment with FDA-approved drugs. It also incorporates novel analogs that are under clinical\ntrials as there is an urgent need for innovative antiviral medications, and enormous global efforts\nare required to find secure and efficient cures for these viral infections.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113894501336800250220051811","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T07:01:13Z","timestamp":1740466873000},"page":"534-550","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unfurling the Potential of Antiviral Agents Aimed for RNA Virus Ailment"],"prefix":"10.2174","volume":"26","author":[{"given":"Ritchu","family":"Babbar","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmeen","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajalpreet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Swikriti","sequence":"additional","affiliation":[{"name":"Department of\nPharmacy, Swami Vivekanand College of Pharmacy, Ramnagar, Banur, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay Dhondiram","family":"Vagh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy,\nNGSPMs College of Pharmacy Brahma Valley Nashik, S.P. Pune University, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Sachdeva","sequence":"additional","affiliation":[{"name":"Department of Pharmacy,\nFatima College of Health Sciences, Al Ain, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Behl","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Amity School of\nPharmaceutical Sciences, Amity University, Mohali, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gulati","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of\nPharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 1444411, India"},{"name":"ARCCIM, Faculty of\nHealth, University of Technology Sydney, Ultimo, NSW, 20227, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Gasmi","sequence":"additional","affiliation":[{"name":"Soci\u00e9t\u00e9 Francophone de Nutrith\u00e9rapie et\nde Nutrig\u00e9n\u00e9tique Appliqu\u00e9e, Villeurbanne, France"},{"name":"Department of Pharmacy, International Institute of Nutrition and\nMicronutrition Sciences, Saint-\u00c9tienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3389\/fmicb.2019.00523","volume":"10","author":"Moelling K.","year":"2019","unstructured":"Moelling K.; Broecker F.; Viruses, and evolution\u2013viruses first? A personal perspective. Front Microbiol  2019,10,523","journal-title":"Front Microbiol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature04160","volume":"437","author":"Suttle C.A.","year":"2005","unstructured":"Suttle C.A.; Viruses in the sea. Nature  2005,437(7057),356-361","journal-title":"Nature"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3390\/v14020426","volume":"14","author":"Claus-Desbonnet H.","year":"2022","unstructured":"Claus-Desbonnet H.; Nikly E.; Nalbantova V.; Karcheva-Bahchevanska D.; Ivanova S.; Pierre G.; Benbassat N.; Katsarov P.; Michaud P.; Lukova P.; Delattre C.; Polysaccharides, and their derivatives as potential antiviral molecules. Viruses  2022,14(2),426","journal-title":"Viruses"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2174\/1389450119666190920153247","volume":"21","author":"Dinesh D.C.","year":"2020","unstructured":"Dinesh D.C.; Tamilarasan S.; Rajaram K.; Bou\u0159a E.; Antiviral drug targets of single-stranded RNA viruses causing chronic human diseases. Curr Drug Targets  2020,21(2),105-124","journal-title":"Curr Drug Targets"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/chemistry4020019","volume":"4","author":"K&#xE1;lai T.","year":"2022","unstructured":"K&#xE1;lai T.; Pongr&#xE1;cz J.E.; M&#xE1;tyus P.; Recent advances in influenza, HIV and SARS-CoV-2 infection prevention and drug treatment\u2014The need for precision medicine. Chemistry (Basel)  2022,4(2),216-258","journal-title":"Chemistry (Basel)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1056\/NEJMe2001126","volume":"382","author":"Perlman S.","year":"2020","unstructured":"Perlman S.; Another decade, another coronavirus. N Engl J Med  2020,382(8),760-762","journal-title":"N Engl J Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","volume":"102","author":"Joshi S.","year":"2021","unstructured":"Joshi S.; Parkar J.; Ansari A.; Vora A.; Talwar D.; Tiwaskar M.; Patil S.; Barkate H.; Role of favipiravir in the treatment of COVID-19. Int J Infect Dis  2021,102,501-508","journal-title":"Int J Infect Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","volume":"55","author":"Lai C.C.","year":"2020","unstructured":"Lai C.C.; Shih T.P.; Ko W.C.; Tang H.J.; Hsueh P.R.; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents  2020,55(3),105924","journal-title":"Int J Antimicrob Agents"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jfma.2020.02.007","volume":"119","author":"Cheng S.C.","year":"2020","unstructured":"Cheng S.C.; Chang Y.C.; Fan Chiang Y.L.; Chien Y.C.; Cheng M.; Yang C.H.; Huang C.H.; Hsu Y.N.; First case of coronavirus disease 2019 (COVID-19) pneumonia in Taiwan. J Formos Med Assoc  2020,119(3),747-751","journal-title":"J Formos Med Assoc"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.kint.2020.03.005","volume":"97","author":"Cheng Y.","year":"2020","unstructured":"Cheng Y.; Luo R.; Wang K.; Zhang M.; Wang Z.; Dong L.; Li J.; Yao Y.; Ge S.; Xu G.; Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int  2020,97(5),829-838","journal-title":"Kidney Int"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"8155","DOI":"10.3390\/ijerph17218155","volume":"17","author":"Rauf A.","year":"2020","unstructured":"Rauf A.; Abu-Izneid T.; Olatunde A.; Ahmed Khalil A.; Alhumaydhi F.A.; Tufail T.; Shariati M.A.; Rebezov M.; Almarhoon Z.M.; Mabkhot Y.N.; Alsayari A.; Rengasamy K.R.R.; COVID-19 pandemic: Epidemiology, etiology, conventional and non-conventional therapies. Int J Environ Res Public Health  2020,17(21),8155","journal-title":"Int J Environ Res Public Health"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11427-020-1637-5","volume":"63","author":"Xu X.","year":"2020","unstructured":"Xu X.; Chen P.; Wang J.; Feng J.; Zhou H.; Li X.; Zhong W.; Hao P.; Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci  2020,63(3),457-460","journal-title":"Sci China Life Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"V\u2019kovski P.","year":"2021","unstructured":"V\u2019kovski P.; Kratzel A.; Steiner S.; Stalder H.; Thiel V.; Coronavirus biology and replication: Implications for SARS-COV-2. Nat Rev Microbiol  2021,19(3),155-170","journal-title":"Nat Rev Microbiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/d41586-020-02544-6","volume":"585","author":"Callaway E.","year":"2020","unstructured":"Callaway E.; The coronavirus is mutating \u2014 does it matter? Nature  2020,585(7824),174-177","journal-title":"Nature"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","volume":"28","author":"van de Veerdonk F.L.","year":"2022","unstructured":"van de Veerdonk F.L.; Giamarellos-Bourboulis E.; Pickkers P.; Derde L.; Leavis H.; van Crevel R.; Engel J.J.; Wiersinga W.J.; Vlaar A.P.J.; Shankar-Hari M.; van der Poll T.; Bonten M.; Angus D.C.; van der Meer J.W.M.; Netea M.G.; A guide to immunotherapy for COVID-19. Nat Med  2022,28(1),39-50","journal-title":"Nat Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1021\/acs.jmedchem.0c01140","volume":"65","author":"Cannalire R","year":"2022","unstructured":"Cannalire R; Tramontano E; Summa V.; Focus on Severe Acute Respiratory Syndrome (SARS) Coronavirus (SARS-CoVs) 1 and 2. New Drug Development for Known and Emerging Viruses  2022,65,2716-2746","journal-title":"New Drug Development for Known and Emerging Viruses"},{"key":"ref=17","year":"2023","unstructured":"National institutes of health the COVID-19 treatment guidelines panel's statement on therapies for high-risk Non-hospitalized Patients with Mild to Moderate COVID-19.  Available from:  https:\/\/www.omeditbretagne.fr\/wp-content\/uploads\/2022\/01\/NIH_covid19treatmentguidelines_161221.pdf2023"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"Warren T.K.","year":"2016","unstructured":"Warren T.K.; Jordan R.; Lo M.K.; Ray A.S.; Mackman R.L.; Soloveva V.; Siegel D.; Perron M.; Bannister R.; Hui H.C.; Larson N.; Strickley R.; Wells J.; Stuthman K.S.; Van Tongeren S.A.; Garza N.L.; Donnelly G.; Shurtleff A.C.; Retterer C.J.; Gharaibeh D.; Zamani R.; Kenny T.; Eaton B.P.; Grimes E.; Welch L.S.; Gomba L.; Wilhelmsen C.L.; Nichols D.K.; Nuss J.E.; Nagle E.R.; Kugelman J.R.; Palacios G.; Doerffler E.; Neville S.; Carra E.; Clarke M.O.; Zhang L.; Lew W.; Ross B.; Wang Q.; Chun K.; Wolfe L.; Babusis D.; Park Y.; Stray K.M.; Trancheva I.; Feng J.Y.; Barauskas O.; Xu Y.; Wong P.; Braun M.R.; Flint M.; McMullan L.K.; Chen S.S.; Fearns R.; Swaminathan S.; Mayers D.L.; Spiropoulou ; Lee W.A.; Nichol S.T.; Cihlar T.; Bavari S.; Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature  2016,531(7594),381-385","journal-title":"Nature"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/covid4060046","volume":"4","year":"2024","unstructured":"Babalola  BA, Adegboyega AE. Computational discovery of novel imidazole derivatives as inhibitors of SARS-CoV-2 main protease: An integrated approach combining molecular dynamics and binding affinity analysis. COVID  2024,4(6),672-695","journal-title":"COVID"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3390\/covid1040061","volume":"1","year":"2021","unstructured":"Babalola BA, Adetobi TE, Akinsuyi OS, Adebisi OA, Folajimi  EO. Computational study of the therapeutic potential of novel heterocyclic derivatives against SARS-CoV-2. COVID  2021,1(4),757-774","journal-title":"COVID"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","volume":"295","author":"Gordon C.J.","year":"2020","unstructured":"Gordon C.J.; Tchesnokov E.P.; Woolner E.; Perry J.K.; Feng J.Y.; Porter D.P.; G&#xF6;tte M.; Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem  2020,295(20),6785-6797","journal-title":"J Biol Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e2021946118","DOI":"10.1073\/pnas.2021946118","volume":"118","author":"Naydenova K.","year":"2021","unstructured":"Naydenova K.; Muir K.W.; Wu L.F.; Zhang Z.; Coscia F.; Peet M.J.; Castro-Hartmann P.; Qian P.; Sader K.; Dent K.; Kimanius D.; Sutherland J.D.; L&#xF6;we J.; Barford D.; Russo C.J.; Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP. Proc Natl Acad Sci USA  2021,118(7),e2021946118","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1002\/1873-3468.14182","volume":"595","author":"Padhi A.K.","year":"2021","unstructured":"Padhi A.K.; Dandapat J.; Saudagar P.; Uversky V.N.; Tripathi T.; Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination. FEBS Lett  2021,595(18),2366-2382","journal-title":"FEBS Lett"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"115099","DOI":"10.1016\/j.biopha.2023.115099","volume":"12","author":"Babalola B.A.","year":"2023","unstructured":"Babalola B.A.; Akinsuyi O.S.; Folajimi E.O.; Olujimi F.; Chikere B.; Adewumagun I.A.; Adetobi T.E.; Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics Biomed Pharmacother  2023,12,115099","journal-title":"Biomed Pharmacother"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"Owen D.R.","year":"2021","unstructured":"Owen D.R.; Allerton C.M.N.; Anderson A.S.; Aschenbrenner L.; Avery M.; Berritt S.; Boras B.; Cardin R.D.; Carlo A.; Coffman K.J.; Dantonio A.; Di L.; Eng H.; Ferre R.; Gajiwala K.S.; Gibson S.A.; Greasley S.E.; Hurst B.L.; Kadar E.P.; Kalgutkar A.S.; Lee J.C.; Lee J.; Liu W.; Mason S.W.; Noell S.; Novak J.J.; Obach R.S.; Ogilvie K.; Patel N.C.; Pettersson M.; Rai D.K.; Reese M.R.; Sammons M.F.; Sathish J.G.; Singh R.S.P.; Steppan C.M.; Stewart A.E.; Tuttle J.B.; Updyke L.; Verhoest P.R.; Wei L.; Yang Q.; Zhu Y.; An oral SARS-CoV-2 M  inhibitor clinical candidate for the treatment of COVID-19. Science  2021,374(6575),1586-1593","journal-title":"Science"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41422-022-00618-w","volume":"32","author":"Li P.","year":"2022","unstructured":"Li P.; Wang Y.; Lavrijsen M.; Lamers M.M.; de Vries A.C.; Rottier R.J.; Bruno M.J.; Peppelenbosch M.P.; Haagmans B.L.; Pan Q.; SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res  2022,32(3),322-324","journal-title":"Cell Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1056\/NEJMc2119407","volume":"386","author":"Takashita E.","year":"2022","unstructured":"Takashita E.; Kinoshita N.; Yamayoshi S.; Sakai-Tagawa Y.; Fujisaki S.; Ito M.; Iwatsuki-Horimoto K.; Chiba S.; Halfmann P.; Nagai H.; Saito M.; Adachi E.; Sullivan D.; Pekosz A.; Watanabe S.; Maeda K.; Imai M.; Yotsuyanagi H.; Mitsuya H.; Ohmagari N.; Takeda M.; Hasegawa H.; Kawaoka Y.; Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant. N Engl J Med  2022,386(10),995-998","journal-title":"N Engl J Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"eabc5332","DOI":"10.1126\/scitranslmed.abc5332","volume":"12","author":"Rathnayake A.D.","year":"2020","unstructured":"Rathnayake A.D.; Zheng J.; Kim Y.; Perera K.D.; Mackin S.; Meyerholz D.K.; Kashipathy M.M.; Battaile K.P.; Lovell S.; Perlman S.; Groutas W.C.; Chang K.O.; 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV\u2013infected mice. Sci Transl Med  2020,12(557),eabc5332","journal-title":"Sci Transl Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41418-021-00900-1","volume":"29","author":"Rona G.","year":"2022","unstructured":"Rona G.; Zeke A.; Miwatani-Minter B.; de Vries M.; Kaur R.; Schinlever A.; Garcia S.F.; Goldberg H.V.; Wang H.; Hinds T.R.; Bailly F.; Zheng N.; Cotelle P.; Desma&#xEB;le D.; Landau N.R.; Dittmann M.; Pagano M.; The NSP14\/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target. Cell Death Differ  2022,29(2),285-292","journal-title":"Cell Death Differ"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.3390\/v12121423","volume":"12","author":"Tampere M.","year":"2020","unstructured":"Tampere M.; Pettke A.; Salata C.; Wallner O.; Koolmeister T.; Cazares-K&#xF6;rner A.; Visnes T.; Hesselman M.C.; Kunold E.; Wiita E.; Kalder&#xE9;n C.; Lightowler M.; Jemth A.S.; Lehti&#xF6; J.; Rosenquist\u00c5.; Warpman-Berglund U.; Helleday T.; Mirazimi A.; Jafari R.; Puumalainen M.R.; Novel broad-spectrum antiviral inhibitors targeting host factors essential for replication of pathogenic RNA viruses. Viruses  2020,12(12),1423","journal-title":"Viruses"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12967-020-02476-9","volume":"18","author":"Chitalia V.C.","year":"2020","unstructured":"Chitalia V.C.; Munawar A.H.; A painful lesson from the COVID-19 pandemic: The need for broad-spectrum, host-directed antivirals. J Transl Med  2020,18(1),390","journal-title":"J Transl Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"671263","DOI":"10.3389\/fmolb.2021.671263","volume":"8","author":"Mei M.","year":"2021","unstructured":"Mei M.; Tan X.; Current strategies of antiviral drug discovery for COVID-19. Front Mol Biosci  2021,8,671263","journal-title":"Front Mol Biosci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"103255","DOI":"10.1016\/j.ebiom.2021.103255","volume":"65","author":"Hoffmann M.","year":"2021","unstructured":"Hoffmann M.; Hofmann-Winkler H.; Smith J.C.; Kr&#xFC;ger N.; Arora P.; S&#xF8;rensen L.K.; S&#xF8;gaard O.S.; Hasselstr&#xF8;m J.B.; Winkler M.; Hempel T.; Raich L.; Olsson S.; Danov O.; Jonigk D.; Yamazoe T.; Yamatsuta K.; Mizuno H.; Ludwig S.; No&#xE9; F.; Kjolby M.; Braun A.; Sheltzer J.M.; P&#xF6;hlmann S.; Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine  2021,65,103255","journal-title":"EBioMedicine"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4274\/tjps.63497","volume":"15","author":"Singh I.","year":"2018","unstructured":"Singh I.; Arora R.; Dhiman H.; Pahwa R.; Carbon quantum dots: Synthesis, characterization and biomedical applications. Turk J Pharm Sci  2018,15(2),219-230","journal-title":"Turk J Pharm Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/bcpt.13533","volume":"128","author":"Breining P.","year":"2021","unstructured":"Breining P.; Fr&#xF8;lund A.L.; H&#xF8;jen J.F.; Gunst J.D.; Staerke N.B.; Saedder E.; Cases-Thomas M.; Little P.; Nielsen L.P.; S&#xF8;gaard O.S.; Kjolby M.; Camostat mesylate against SARS-CoV-2 and COVID-19\u2014Rationale, dosing and safety. Basic Clin Pharmacol Toxicol  2021,128(2),204-212","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"652688","DOI":"10.3389\/fphar.2021.652688","volume":"12","author":"Sukhatme V.P.","year":"2021","unstructured":"Sukhatme V.P.; Reiersen A.M.; Vayttaden S.J.; Sukhatme V.V.; Fluvoxamine: A review of its mechanism of action and its role in COVID-19. Front Pharmacol  2021,12,652688","journal-title":"Front Pharmacol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1038\/s41380-021-01432-3","volume":"27","author":"Hashimoto Y.","year":"2022","unstructured":"Hashimoto Y.; Suzuki T.; Hashimoto K.; Mechanisms of action of fluvoxamine for COVID-19: A historical review. Mol Psychiatry  2022,27(4),1898-1907","journal-title":"Mol Psychiatry"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.4269\/ajtmh.20-0271","volume":"102","author":"Chaccour C.","year":"2020","unstructured":"Chaccour C.; Hammann F.; Ram&#xF3;n-Garc&#xED;a S.; Rabinovich N.R.; Ivermectin and COVID-19: Keeping rigor in times of urgency. Am J Trop Med Hyg  2020,102(6),1156-1157","journal-title":"Am J Trop Med Hyg"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","volume":"178","author":"Caly L.","year":"2020","unstructured":"Caly L.; Druce J.D.; Catton M.G.; Jans D.A.; Wagstaff K.M.; The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res  2020,178,104787","journal-title":"Antiviral Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41429-021-00491-6","volume":"75","author":"Zaidi A.K.","year":"2022","unstructured":"Zaidi A.K.; Dehgani-Mobaraki P.; The mechanisms of action of ivermectin against SARS-CoV-2\u2014an extensive review. J Antibiot (Tokyo)  2022,75(2),60-71","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"17067","DOI":"10.1016\/S0021-9258(19)47340-7","volume":"266","author":"Lytton J.","year":"1991","unstructured":"Lytton J.; Westlin M.; Hanley M.R.; Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biol Chem  1991,266(26),17067-17071","journal-title":"J Biol Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"35100","DOI":"10.1038\/srep35100","volume":"6","author":"Losada A.","year":"2016","unstructured":"Losada A.; Mu&#xF1;oz-Alonso M.J.; Garc&#xED;a C.; S&#xE1;nchez-Murcia P.A.; Mart&#xED;nez-Leal J.F.; Dom&#xED;nguez J.M.; Lillo M.P.; Gago F.; Galmarini C.M.; Translation elongation factor eEF1A2 is a novel anticancer target for the marine natural product plitidepsin. Sci Rep  2016,6(1),35100","journal-title":"Sci Rep"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.abf4058","volume":"371","author":"White K.M.","year":"2021","unstructured":"White K.M.; Rosales R.; Yildiz S.; Kehrer T.; Miorin L.; Moreno E.; Jangra S.; Uccellini M.B.; Rathnasinghe R.; Coughlan L.; Martinez-Romero C.; Batra J.; Rojc A.; Bouhaddou M.; Fabius J.M.; Obernier K.; Dejosez M.; Guill&#xE9;n M.J.; Losada A.; Avil&#xE9;s P.; Schotsaert M.; Zwaka T.; Vignuzzi M.; Shokat K.M.; Krogan N.J.; Garc&#xED;a-Sastre A.; Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science  2021,371(6532),926-931","journal-title":"Science"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s40495-020-00226-5","volume":"6","author":"Kumari P.","year":"2020","unstructured":"Kumari P.; Rawat K.; Saha L.; Pipeline pharmacological therapies in clinical trial for COVID-19 pandemic: A recent update. Curr Pharmacol Rep  2020,6(5),228-240","journal-title":"Curr Pharmacol Rep"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"aaa4339","DOI":"10.1126\/science.aaa4339","volume":"347","author":"Heesterbeek H.","year":"2015","unstructured":"Heesterbeek H.; Anderson R.M.; Andreasen V.; Bansal S.; De Angelis D.; Dye C.; Eames K.T.D.; Edmunds W.J.; Frost S.D.W.; Funk S.; Hollingsworth T.D.; House T.; Isham V.; Klepac P.; Lessler J.; Lloyd-Smith J.O.; Metcalf C.J.E.; Mollison D.; Pellis L.; Pulliam J.R.C.; Roberts M.G.; Viboud C.; Modeling infectious disease dynamics in the complex landscape of global health. Science  2015,347(6227),aaa4339","journal-title":"Science"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e0136186","DOI":"10.1371\/journal.pone.0136186","volume":"10","author":"Mosnier A.","year":"2015","unstructured":"Mosnier A.; Caini S.; Daviaud I.; Nauleau E.; Bui T.T.; Debost E.; Bedouret B.; Agius G.; van der Werf S.; Lina B.; Cohen J.M.; Clinical characteristics are similar across type A and B influenza virus infections. PLoS One  2015,10(9),e0136186","journal-title":"PLoS One"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ng.3479","volume":"48","author":"Poon L.L.M.","year":"2016","unstructured":"Poon L.L.M.; Song T.; Rosenfeld R.; Lin X.; Rogers M.B.; Zhou B.; Sebra R.; Halpin R.A.; Guan Y.; Twaddle A.; DePasse J.V.; Stockwell T.B.; Wentworth D.E.; Holmes E.C.; Greenbaum B.; Peiris J.S.M.; Cowling B.J.; Ghedin E.; Quantifying influenza virus diversity and transmission in humans. Nat Genet  2016,48(2),195-200","journal-title":"Nat Genet"},{"key":"ref=48","first-page":"iii","volume":"7","author":"Turner D","year":"2003","unstructured":"Turner D; Wailoo A; Nicholson K; Cooper N; Sutton A; Abrams K; Systematic review and economic decision modelling for the prevention and treatment of influenza A and B Winchester, England. Heal Technol Assess  2003,7(35),iii-v","journal-title":"Heal Technol Assess"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3201\/eid1904.120903","volume":"19","author":"Fuller T.L.","year":"2013","unstructured":"Fuller T.L.; Gilbert M.; Martin V.; Cappelle J.; Hosseini P.; Njabo K.Y.; Abdel Aziz S.; Xiao X.; Daszak P.; Smith T.B.; Predicting hotspots for influenza virus reassortment. Emerg Infect Dis  2013,19(4),581-588","journal-title":"Emerg Infect Dis"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/nrd2175","volume":"5","author":"De Clercq E.","year":"2006","unstructured":"De Clercq E.; Antiviral agents active against influenza A viruses. Nat Rev Drug Discov  2006,5(12),1015-1025","journal-title":"Nat Rev Drug Discov"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1269344","DOI":"10.3389\/fcimb.2023.1269344","volume":"13","author":"Meseko C.","year":"2023","unstructured":"Meseko C.; Sanicas M.; Asha K.; Sulaiman L.; Kumar B.; Antiviral options and therapeutics against influenza: History, latest developments and future prospects. Front Cell Infect Microbiol  2023,13,1269344","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/infdis\/jis726","volume":"207","author":"Muthuri S.G.","year":"2013","unstructured":"Muthuri S.G.; Myles P.R.; Venkatesan S.; Leonardi-Bee J.; Nguyen- Van-Tam J.S.; Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: A systematic review and meta-analysis in hospitalized patients. J Infect Dis  2013,207(4),553-563","journal-title":"J Infect Dis"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/S0140-6736(03)14854-4","volume":"362","author":"Nicholson K.G.","year":"2003","unstructured":"Nicholson K.G.; Wood J.M.; Zambon M.; Influenza. Lancet  2003,362(9397),1733-1745","journal-title":"Lancet"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3390\/ani13071153","volume":"13","author":"Pellegrini F.","year":"2023","unstructured":"Pellegrini F.; Buonavoglia A.; Omar A.H.; Diakoudi G.; Lucente M.S.; Odigie A.E.; Sposato A.; Augelli R.; Camero M.; Decaro N.; Elia G.; B&#xE1;nyai K.; Martella V.; Lanave G.; A cold case of equine influenza disentangled with nanopore sequencing. Animals (Basel)  2023,13(7),1153","journal-title":"Animals (Basel)"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.bbrc.2014.12.102","volume":"457","author":"Matsuda K.","year":"2015","unstructured":"Matsuda K.; Hattori S.; Kariya R.; Komizu Y.; Kudo E.; Goto H.; Taura M.; Ueoka R.; Kimura S.; Okada S.; Inhibition of HIV-1 entry by the tricyclic coumarin GUT-70 through the modification of membrane fluidity. Biochem Biophys Res Commun  2015,457(3),288-294","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"e2119151","DOI":"10.1001\/jamanetworkopen.2021.19151","volume":"4","author":"Liu J.W.","year":"2021","unstructured":"Liu J.W.; Lin S.H.; Wang L.C.; Chiu H.Y.; Lee J.A.; Comparison of antiviral agents for seasonal influenza outcomes in healthy adults and children: A systematic review and network meta-analysis. JAMA Netw Open  2021,4(8),e2119151","journal-title":"JAMA Netw Open"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/ph15010028","volume":"15","author":"Dufrasne F.","year":"2021","unstructured":"Dufrasne F.; Baloxavir marboxil: An original new drug against influenza. Pharmaceuticals (Basel)  2021,15(1),28","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jmii.2021.04.002","volume":"54","author":"Kuo Y.C.","year":"2021","unstructured":"Kuo Y.C.; Lai C.C.; Wang Y.H.; Chen C.H.; Wang C.Y.; Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials. J Microbiol Immunol Infect  2021,54(5),865-875","journal-title":"J Microbiol Immunol Infect"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.bsheal.2020.04.004","volume":"2","author":"Fang Q.","year":"2020","unstructured":"Fang Q.; Wang D.; Advanced researches on the inhibition of influenza virus by Favipiravir and Baloxavir. Biosaf Heal  2020,2(2),64-70","journal-title":"Biosaf Heal"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Furuta Y.","year":"2017","unstructured":"Furuta Y.; Komeno T.; Nakamura T.; Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci  2017,93(7),449-463","journal-title":"Proc Jpn Acad, Ser B, Phys Biol Sci"},{"key":"ref=61","doi-asserted-by":"publisher","DOI":"10.36233\/0372-9311-114","volume":"98","author":"Zhirnov O","year":"2021","unstructured":"Zhirnov O; Chernyshova A.;  Favipiravir: The hidden threat of mutagenic action  2021,98(2)","journal-title":"Favipiravir: The hidden threat of mutagenic action"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3389\/fimmu.2019.00531","volume":"10","author":"Pizzorno A.","year":"2019","unstructured":"Pizzorno A.; Padey B.; Terrier O.; Rosa-Calatrava M.; Drug repurposing approaches for the treatment of influenza viral infection: Reviving old drugs to fight against a long-lived enemy. Front Immunol  2019,10,531","journal-title":"Front Immunol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3390\/v12111242","volume":"12","author":"Jennings M.R.","year":"2020","unstructured":"Jennings M.R.; Parks R.J.; Curcumin as an antiviral agent. Viruses  2020,12(11),1242","journal-title":"Viruses"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.3390\/molecules26092593","volume":"26","author":"Terrier O.","year":"2021","unstructured":"Terrier O.; Dilly S.; Pizzorno A.; Chalupska D.; Humpolickova J.; Bou\u0159a E.; Berenbaum F.; Quideau S.; Lina B.; F&#xE8;ve B.; Adnet F.; Sabbah M.; Rosa-Calatrava M.; Mar&#xE9;chal V.; Henri J.; Slama-Schwok A.; Antiviral properties of the NSAID drug naproxen targeting the nucleoprotein of SARS-CoV-2 coronavirus. Molecules  2021,26(9),2593","journal-title":"Molecules"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"e01432-20","DOI":"10.1128\/JVI.01432-20","volume":"95","author":"Yang F.","year":"2021","unstructured":"Yang F.; Pang B.; Lai K.K.; Cheung N.N.; Dai J.; Zhang W.; Zhang J.; Chan K.H.; Chen H.; Sze K.H.; Zhang H.; Hao Q.; Yang D.; Yuen K.Y.; Kao R.Y.; Discovery of a novel specific inhibitor targeting influenza A virus nucleoprotein with pleiotropic inhibitory effects on various steps of the viral life cycle. J Virol  2021,95(9),e01432-20","journal-title":"J Virol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1089\/adt.2015.0003.drrr","volume":"13","author":"Perwitasari O.","year":"2015","unstructured":"Perwitasari O.; Yan X.; O\u2019Donnell J.; Johnson S.; Tripp R.A.; Repurposing kinase inhibitors as antiviral agents to control influenza a virus replication. Assay Drug Dev Technol  2015,13(10),638-649","journal-title":"Assay Drug Dev Technol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/dna.2017.4033","volume":"37","author":"Schor S.","year":"2018","unstructured":"Schor S.; Einav S.; Repurposing of kinase inhibitors as broad-spectrum antiviral drugs. DNA Cell Biol  2018,37(2),63-69","journal-title":"DNA Cell Biol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/v11020171","volume":"11","author":"Meineke R.","year":"2019","unstructured":"Meineke R.; Rimmelzwaan G.F.; Elbahesh H.; Influenza virus infections and cellular kinases. Viruses  2019,11(2),171","journal-title":"Viruses"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejps.2019.03.020","volume":"133","author":"Zhang J.","year":"2019","unstructured":"Zhang J.; Hu Y.; Hau R.; Musharrafieh R.; Ma C.; Zhou X.; Chen Y.; Wang J.; Identification of NMS-873, an allosteric and specific p97 inhibitor, as a broad antiviral against both influenza A and B viruses. Eur J Pharm Sci  2019,133,86-94","journal-title":"Eur J Pharm Sci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/v13040624","volume":"13","author":"Bai Y.","year":"2021","unstructured":"Bai Y.; Jones J.C.; Wong S.S.; Zanin M.; Antivirals targeting the surface glycoproteins of influenza virus: Mechanisms of action and resistance. Viruses  2021,13(4),624","journal-title":"Viruses"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fimmu.2019.00060","volume":"10","author":"Pizzorno A.","year":"2019","unstructured":"Pizzorno A.; Terrier O.; Nicolas de Lamballerie C.; Julien T.; Padey B.; Traversier A.; Roche M.; Hamelin M.E.; Rh&#xE9;aume C.; Croze S.; Escuret V.; Poissy J.; Lina B.; Legras-Lachuer C.; Textoris J.; Boivin G.; Rosa-Calatrava M.; Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures. Front Immunol  2019,10,60","journal-title":"Front Immunol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","volume":"14","author":"Haffizulla J.","year":"2014","unstructured":"Haffizulla J.; Hartman A.; Hoppers M.; Resnick H.; Samudrala S.; Ginocchio C.; Bardin M.; Rossignol J.F.; Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: A double-blind, randomised, placebo-controlled, phase 2b\/3 trial. Lancet Infect Dis  2014,14(7),609-618","journal-title":"Lancet Infect Dis"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S1473-3099(17)30476-0","volume":"17","author":"Beigel J.H.","year":"2017","unstructured":"Beigel J.H.; Bao Y.; Beeler J.; Manosuthi W.; Slandzicki A.; Dar S.M.; Panuto J.; Beasley R.L.; Perez-Patrigeon S.; Suwanpimolkul G.; Losso M.H.; McClure N.; Bozzolo D.R.; Myers C.; Holley H.P.; Hoopes J.; Lane H.C.; Hughes M.D.; Davey R.T.; Winnie M.; Dinh D.V.; Seethala R.; Garcia H.; Pouzar J.; Seep M.; Riffer E.; Bart B.; Dar S.; Hoppers M.; Panuto J.; Rowe H.; Slandzicki A.; Wolfe C.; Desantis D.; Baynton B.; Beasley R.L.; Markowitz N.; Stearns Z.A.; Cho J.; Goisse M.; Wolf T.A.; Kay J.; Dharan N.; Fitzgibbons W.; Woodruff M.; Bell T.; Lenzmeier T.; Schooley R.; Elie M-C.; Winokur P.; Finberg R.; Hurt C.; Tebas P.; Sattler F.R.; Ampajwala M.; Batts D.; Bloch M.; Moore R.; Dwyer D.; Romo-Garcia J.; Patrigeon S.P.; Zulueta A.P.R.; Manosuthi W.; Chetchotisakd P.; Ruxrungtham K.; Avihingsanon A.; Suwanpimolkul G.; Ratanasuwan W.; Lupo S.; Trape L.; Losso M.H.; Macias L.M.; Lopardo G.; Barcelona L.; Mykietuk A.; Alzogaray M.F.; Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: A multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis  2017,17(12),1255-1265","journal-title":"Lancet Infect Dis"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fcimb.2020.00016","volume":"10","author":"Xu L.","year":"2020","unstructured":"Xu L.; Jiang W.; Jia H.; Zheng L.; Xing J.; Liu A.; Du G.; Discovery of multitarget-directed ligands against influenza a virus from compound yizhihao through a predictive system for compound-protein interactions. Front Cell Infect Microbiol  2020,10,16","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/pathogens9121020","volume":"9","author":"Wieczorek K.","year":"2020","unstructured":"Wieczorek K.; Szutkowska B.; Kierzek E.; Anti-influenza strategies based on nanoparticle applications. Pathogens  2020,9(12),1020","journal-title":"Pathogens"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"110298","DOI":"10.1016\/j.mehy.2020.110298","volume":"144","author":"Chan Y.","year":"2020","unstructured":"Chan Y.; Ng S.W.; Mehta M.; Anand K.; Kumar Singh S.; Gupta G.; Chellappan D.K.; Dua K.; Advanced drug delivery systems can assist in managing influenza virus infection: A hypothesis. Med Hypotheses  2020,144,110298","journal-title":"Med Hypotheses"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"e03679","DOI":"10.7554\/eLife.03679","volume":"3","author":"Arias A.","year":"2014","unstructured":"Arias A.; Thorne L.; Goodfellow I.; Favipiravir elicits antiviral mutagenesis during virus replication in vivo. eLife  2014,3,e03679","journal-title":"eLife"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1093\/cid\/ciw571","volume":"63","author":"Bai C.Q.","year":"2016","unstructured":"Bai C.Q.; Mu J.S.; Kargbo D.; Song Y.B.; Niu W.K.; Nie W.M.; Kanu A.; Liu W.W.; Wang Y.P.; Dafae F.; Yan T.; Hu Y.; Deng Y.Q.; Lu H.J.; Yang F.; Zhang X.G.; Sun Y.; Cao Y.X.; Su H.X.; Sun Y.; Liu W.S.; Wang C.Y.; Qian J.; Liu L.; Wang H.; Tong Y.G.; Liu Z.Y.; Chen Y.S.; Wang H.Q.; Kargbo B.; Gao G.F.; Jiang J.F.; Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705)\u2014Sierra Leone, 2014. Clin Infect Dis  2016,63(10),1288-1294","journal-title":"Clin Infect Dis"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.3390\/v7092850","volume":"7","author":"Li T.","year":"2015","unstructured":"Li T.; Chan M.; Lee N.; Clinical implications of antiviral resistance in influenza. Viruses  2015,7(9),4929-4944","journal-title":"Viruses"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5365\/wpsar.2015.6.3.005","volume":"7","author":"Merritt T.","year":"2016","unstructured":"Merritt T.; Hope K.; Butler M.; Durrheim D.; Gupta L.; Najjar Z.; Conaty S.; Boonwaat L.; Fletcher S.; Effect of antiviral prophylaxis on influenza outbreaks in aged care facilities in three local health districts in New South Wales, Australia, 2014. Western Pac Surveill Response J  2016,7(1),14-20","journal-title":"Western Pac Surveill Response J"},{"key":"ref=81","first-page":"1","volume":"60","author":"Bresee JS","year":"2011","unstructured":"Bresee JS; Fiore AE; Fry A; Gubareva LV; Shay DK; Uyeki TM; Antiviral agents for the treatment and chemoprophylaxis of influenza: Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep  2011,60(1),1-24","journal-title":"MMWR Recomm Rep"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1128\/mr.57.1.183-289.1993","volume":"57","author":"Levy J.A.","year":"1993","unstructured":"Levy J.A.; Pathogenesis of human immunodeficiency virus infection. Microbiol Rev  1993,57(1),183-289","journal-title":"Microbiol Rev"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/scientificamerican1088-52","volume":"259","author":"Haseltine W.A.","year":"1988","unstructured":"Haseltine W.A.; Wong-Staal F.; The molecular biology of the AIDS virus. Sci Am  1988,259(4),52-62","journal-title":"Sci Am"},{"key":"ref=84","author":"Justiz Vaillant A.A.","year":"2022","unstructured":"Justiz Vaillant A.A.; Gulick P.G.; HIV disease current practice. StatPearls  2022","journal-title":"StatPearls"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/viro.1998.9398","volume":"251","author":"Freed E.O.","year":"1998","unstructured":"Freed E.O.; HIV-1 gag proteins: Diverse functions in the virus life cycle. Virology  1998,251(1),1-15","journal-title":"Virology"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1006\/viro.1994.1339","volume":"202","author":"Berkowitz R.D.","year":"1994","unstructured":"Berkowitz R.D.; Goff S.P.; Analysis of binding elements in the human immunodeficiency virus type 1 genomic RNA and nucleocapsid protein. Virology  1994,202(1),233-246","journal-title":"Virology"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"6445","DOI":"10.1128\/jvi.69.10.6445-6456.1995","volume":"69","author":"Berkowitz R.D.","year":"1995","unstructured":"Berkowitz R.D.; Ohagen A.; H&#xF6;glund S.; Goff S.P.; Retroviral nucleocapsid domains mediate the specific recognition of genomic viral RNAs by chimeric Gag polyproteins during RNA packaging in vivo. J Virol  1995,69(10),6445-6456","journal-title":"J Virol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"117876","DOI":"10.1016\/j.bmc.2024.117876","volume":"112","author":"Babalola B.A.","year":"2024","unstructured":"Babalola B.A.; Sharma L.; Olowokere O.; Malik M.; Folajimi O.; Advancing drug discovery: Thiadiazole derivatives as multifaceted agents in medicinal chemistry and pharmacology Bioorg Med Chem  2024,112,117876","journal-title":"Bioorg Med Chem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1126\/science.1217550","volume":"335","author":"Chahroudi A.","year":"2012","unstructured":"Chahroudi A.; Bosinger S.E.; Vanderford T.H.; Paiardini M.; Silvestri G.; Natural SIV hosts: Showing AIDS the door. Science  2012,335(6073),1188-1193","journal-title":"Science"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"101565","DOI":"10.1016\/j.rechem.2024.101565","volume":"8","author":"Babalola B.A.","unstructured":"Babalola B.A.; Malik M.; Sharma L.; Olowokere O.; Folajimi O.; Exploring the therapeutic potential of phenothiazine derivatives in medicinal chemistry. Resul Chemi  ,8(2024),101565","journal-title":"Resul Chemi"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1146\/annurev.immunol.18.1.665","volume":"18","author":"Pierson T.","year":"2000","unstructured":"Pierson T.; McArthur J.; Siliciano R.F.; Reservoirs for HIV-1: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol  2000,18(1),665-708","journal-title":"Annu Rev Immunol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"6096134","DOI":"10.1155\/2017\/6096134","volume":"2017","author":"Xu W","year":"2017","unstructured":"Xu W; Li H; Wang Q; Hua C; Zhang H; Li W; Jiang S; Lu L; Advancements in developing strategies for sterilizing and functional HIV cures. BioMed Res Int  2017,2017,6096134","journal-title":"BioMed Res Int"},{"key":"ref=93","year":"2022","unstructured":"U.S Food and drug administration FDA approves first injectable treatment for hiv pre-exposure prevention.  2022"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","volume":"382","author":"Kozal M.","year":"2020","unstructured":"Kozal M.; Aberg J.; Pialoux G.; Cahn P.; Thompson M.; Molina J.M.; Grinsztejn B.; Diaz R.; Castagna A.; Kumar P.; Latiff G.; DeJesus E.; Gummel M.; Gartland M.; Pierce A.; Ackerman P.; Llamoso C.; Lataillade M.; Fostemsavir in adults with multidrug-resistant HIV-1 infection. N Engl J Med  2020,382(13),1232-1243","journal-title":"N Engl J Med"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"e740","DOI":"10.1016\/S2352-3018(20)30240-X","volume":"7","author":"Lataillade M.","year":"2020","unstructured":"Lataillade M.; Lalezari J.P.; Kozal M.; Aberg J.A.; Pialoux G.; Cahn P.; Thompson M.; Molina J.M.; Moreno S.; Grinsztejn B.; Diaz R.S.; Castagna A.; Kumar P.N.; Latiff G.H.; De Jesus E.; Wang M.; Chabria S.; Gartland M.; Pierce A.; Ackerman P.; Llamoso C.; Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 brighte study. Lancet HIV  2020,7(11),e740-e751","journal-title":"Lancet HIV"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/QAD.0000000000002851","volume":"35","author":"Ackerman P.","year":"2021","unstructured":"Ackerman P.; Thompson M.; Molina J.M.; Aberg J.; Cassetti I.; Kozal M.; Castagna A.; Martins M.; Ramgopal M.; Sprinz E.; Trevi&#xF1;o-P&#xE9;rez S.; Streinu-Cercel A.; Latiff G.H.; Pialoux G.; Kumar P.N.; Wang M.; Chabria S.; Pierce A.; Llamoso C.; Lataillade M.; Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment- experienced adults with HIV-1. AIDS  2021,35(7),1061-1072","journal-title":"AIDS"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","volume":"385","author":"Turkova A.","year":"2021","unstructured":"Turkova A.; White E.; Mujuru H.A.; Kekitiinwa A.R.; Kityo C.M.; Violari A.; Lugemwa A.; Cressey T.R.; Musoke P.; Variava E.; Cotton M.F.; Archary M.; Puthanakit T.; Behuhuma O.; Kobbe R.; Welch S.B.; Bwakura-Dangarembizi M.; Amuge P.; Kaudha E.; Barlow-Mosha L.; Makumbi S.; Ramsagar N.; Ngampiyaskul C.; Musoro G.; Atwine L.; Liberty A.; Musiime V.; Bbuye D.; Ahimbisibwe G.M.; Chalermpantmetagul S.; Ali S.; Sarfati T.; Wynne B.; Shakeshaft C.; Colbers A.; Klein N.; Bernays S.; Sa&#xEF;di Y.; Coelho A.; Grossele T.; Compagnucci A.; Giaquinto C.; Rojo P.; Ford D.; Gibb D.M.; Dolutegravir as first-or second-line treatment for HIV-1 infection in children. N Engl J Med  2021,385(27),2531-2543","journal-title":"N Engl J Med"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12977-021-00569-x","volume":"18","author":"Nickoloff-Bybel E.A.","year":"2021","unstructured":"Nickoloff-Bybel E.A.; Festa L.; Meucci O.; Gaskill P.J.; Co-receptor signaling in the pathogenesis of neuroHIV. Retrovirology  2021,18(1),24","journal-title":"Retrovirology"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/adt.2015.639","volume":"13","author":"Marin M.","year":"2015","unstructured":"Marin M.; Du Y.; Giroud C.; Kim J.H.; Qui M.; Fu H.; Melikyan G.B.; High-throughput HIV\u2013Cell fusion assay for discovery of virus entry inhibitors. Assay Drug Dev Technol  2015,13(3),155-166","journal-title":"Assay Drug Dev Technol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"2007214","DOI":"10.1002\/smll.202007214","volume":"17","author":"Overeem N.J.","year":"2021","unstructured":"Overeem N.J.; van der Vries E.; Huskens J.; A dynamic, supramolecular view on the multivalent interaction between influenza virus and host cell. Small  2021,17(13),2007214","journal-title":"Small"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.3390\/molecules26175305","volume":"26","author":"Cunha R.F.","year":"2021","unstructured":"Cunha R.F.; Sim&#xF5;es S.; Carvalheiro M.; Pereira J.M.A.; Costa Q.; Ascenso A.; Novel antiretroviral therapeutic strategies for HIV. Molecules  2021,26(17),5305","journal-title":"Molecules"},{"key":"ref=102","author":"Judith S.","year":"2021","unstructured":"Judith S.; Leronlimab FDA Approval Status.  Available from:  https:\/\/www.drugs.com\/history\/leronlimab.html (Accessed on: Jan 17 2022).2021"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.3389\/fmicb.2020.01314","volume":"11","author":"Ivanov S.","year":"2020","unstructured":"Ivanov S.; Lagunin A.; Filimonov D.; Tarasova O.; Network-based analysis of OMICs data to understand HIV\u2013host interaction. Front Microbiol  2020,11,1314","journal-title":"Front Microbiol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2165\/11537960-000000000-00000","volume":"70","author":"Boltz D.A.","year":"2010","unstructured":"Boltz D.A.; Aldridge J.R.; Webster R.G.; Govorkova E.A.; Drugs in development for influenza. Drugs  2010,70(11),1349-1362","journal-title":"Drugs"},{"key":"ref=105","author":"Collins S.","year":"2021","unstructured":"Collins S.; Pipeline report 2021: HIV drugs in development, published by HIV i-Base.  Available from:  https:\/\/i-base.info\/htb\/411422021"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501336800250220051811","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/239764\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501336800250220051811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:33:03Z","timestamp":1751517183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/239764\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":105,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501336800250220051811","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}